Thiocarboxamides (i.e., Compounds Containing -c(=s)-hnh, Wherein Substitution May Be Made For Hydrogen Only) Patents (Class 564/74)
  • Patent number: 9630943
    Abstract: The present invention relates to novel tetrahydronaphthyl(thio) carboxamides, to processes for preparing these compounds, to compositions comprising these compounds, and to the use thereof as biologically active compounds, especially for control of harmful microorganisms in crop protection and in the protection of materials
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: April 25, 2017
    Assignee: BAYER CROPSCIENCE AG
    Inventors: Simon Maechling, Pierre-Yves Coqueron, Mazen Es-Sayed, Alexander Sudau, Ulrike Wachendorff-Neumann, Lionel Carles, Christophe Dubost, Jean-Pierre Vors, Stephane Brunet
  • Patent number: 9382193
    Abstract: The disclosure relates to methods for producing amide bonds and reagents related thereto. In some embodiments, the disclosure relates to methods of producing an amide comprising mixing an O-silylated thionoester and an amine under conditions such that an amide is formed. In another embodiment, the disclosure relates to mixing a thiolacid, a silylating agent, and an amine under conditions such that an amide is formed.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: July 5, 2016
    Assignee: Emory University
    Inventors: Lanny S. Liebeskind, Wenting Wu, Zhihui Zhang, Hao Li, Angus A. Lamar
  • Patent number: 9051250
    Abstract: At least 70% by weight of Compound 1 is the single crystalline form, Form A, Form C, or Form D, of the compound. A pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent, and compound 1, wherein at least 70% by weight of the compound is the single crystalline form, Form A, Form C, or Form D, of the compound. A method of treating a subject with cancer comprises administering to the subject an effective amount of compound 1 or the pharmaceutical composition.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: June 9, 2015
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Elena Kostik, Lijun Sun, Joanna Dziewiszek, Jun Y. Choi
  • Publication number: 20150025042
    Abstract: Disclosed are compounds of formulae (I), (III), (IV), (VII), (X), (XI), (XII), (XIII) and (XIV), wherein the variables are as defined in the claims, and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 16, 2013
    Publication date: January 22, 2015
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Shoujun Chen, Keizo Koya, Zachary Demko, Lijun Sun
  • Patent number: 8853393
    Abstract: The invention discloses a novel intermediate for preparing tapentadol and analogues thereof, wherein the structural formula is shown as formula I or II, and the groups are defined as the specification. The invention further discloses a method for preparing the novel intermediate and use of the intermediate for preparing tapentadol and analogues thereof. The invention can remarkably improve the product yield and quality of tapentadol, reduce the production cost, and simplify the production procedure. The preparation process is environment friendly, thus more suitable for the requirements of industrial production.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: October 7, 2014
    Assignee: Anhui New Star Pharmaceutical Development Co., Ltd.
    Inventors: Ziao Xu, Yuanhai Zhao, Degang Li, Xiaoxiang Li
  • Publication number: 20140296343
    Abstract: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.
    Type: Application
    Filed: March 31, 2014
    Publication date: October 2, 2014
    Inventors: Frank M. LONGO, Stephen M. MASSA, Sandeep GUPTA
  • Patent number: 8785451
    Abstract: Disclosed are compounds of formula (IA), formula (IV) or formula (V), wherein the variables are as defined herein, and pharmaceutical compositions containing them which are useful for treating a subject with a proliferative disorder, such as cancer. The disclosed compounds and pharmaceutical compositions are also useful for treating disorders responsive to Hsp70 induction and/or natural killer induction.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: July 22, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Keizo Koya, Lijun Sun, Shoujun Chen, Jun Jiang
  • Patent number: 8785690
    Abstract: A thioamide compound represented by the following general formula (1): wherein, in the general formula (1), R1 represents one of —OR11 and —NR12R13; R2 and R3 each independently represent one of a protecting group of an amide group and a hydrogen atom; the R11 represents one of a protecting group of a hydroxyl group and a hydrogen atom; and the R12 and R13 each independently represent one of a protecting group of an amino group and a hydrogen atom, where the R12 and R13 may together form a protecting group having a cyclic structure.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: July 22, 2014
    Assignee: Microbial Chemistry Research Foundation
    Inventors: Masakatsu Shibasaki, Naoya Kumagai
  • Publication number: 20140171641
    Abstract: Disclosed is a process for making diastereomeric N-sulfinyl ?-amino amides by reaction of chiral sulfinimines with formamides and lithium diisopropylamide. The process of the invention provides the N-sulfinyl ?-amino amides in high yields and with high diastereoselectivity.
    Type: Application
    Filed: November 5, 2013
    Publication date: June 19, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Jonathan Timothy REEVES, Chris H. SENANAYAKE
  • Patent number: 8680100
    Abstract: The present invention is directed to compounds represented by structural formula (I), or a pharmaceutically acceptable salt or a transition metal chelate, coordinate or complex thereof or a transition metal chelate, coordinate or complex of a deprotonated form of the compound. Pharmaceutical composition and method of use for these compounds are also included.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: March 25, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Jun Jiang, Teresa Kowalczyk-Przewloka, Stefan M. Schweizer, Zhi-Qiang Xia, Shoujun Chen, Christopher Borella, Lijun Sun
  • Patent number: 8673980
    Abstract: This invention relates to the field of biologically active compounds and specifically to closthioamides, pharmaceutical compositions comprising these compounds, and their use as antibiotic, antifungal, and/or cytotoxic agent.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: March 18, 2014
    Assignee: Leibniz-Institut fuer Naturstoff-Forschung und Infektionsbiologie
    Inventors: Swantje Behnken, Hans-Martin Dahse, Christian Hertweck, Keishi Ishida, Thorger Lincke, Martin Roth, Florian Kloss
  • Patent number: 8637575
    Abstract: The present invention provides new tyrphostin derivatives acting as protein kinase (PK) and receptor kinase (RK) signaling modulators. The invention further provides methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PK and RK related disorders such as metabolic, inflammatory, fibrotic, and cell proliferative disorders, in particular cancer.
    Type: Grant
    Filed: June 7, 2009
    Date of Patent: January 28, 2014
    Assignee: Novotyr Therapeutics Ltd.
    Inventors: Hadas Reuveni, Alexander Levitzki, Revital Sasson, Andre C. B. Lucassen
  • Patent number: 8637704
    Abstract: At least 70% by weight of Compound 1 is the single crystalline form, Form A, Form C, or Form D, of the compound. A pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent, and compound 1, wherein at least 70% by weight of the compound is the single crystalline form, Form A, Form C, or Form D, of the compound. A method of treating a subject with cancer comprises administering to the subject an effective amount of compound 1 or the pharmaceutical composition.
    Type: Grant
    Filed: November 28, 2008
    Date of Patent: January 28, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Elena Kostik, Lijun Sun, Joanna Dziewiszek, Jun Y. Choi
  • Patent number: 8637496
    Abstract: The invention relates to the use of compounds having a monogalactosyldiacylglycerol (MGDG) synthase inhibitory activity as herbicide or algaecide, and to herbicide and algaecide compositions containing at least one of these compounds.
    Type: Grant
    Filed: June 2, 2008
    Date of Patent: January 28, 2014
    Assignees: Commissariat a l'Energie Atomique, Centre National de la Recherche Scientifique
    Inventors: Anne-Laure Bonneau, Cyrille Botte, Michael Deligny, Nadia Saidani, Hélène Hardre, Bernard Rousseau, Roman Lopez, Eric Marechal
  • Patent number: 8633323
    Abstract: Disclosed herein are methods of preparing a bis(thio-hydrazide amides) compounds of the following structural formula: wherein R1, R2, R3, R4, R5, R6 and R13 are defined herein.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: January 21, 2014
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Jun Jiang, Lijun Sun, Keizo Koya
  • Publication number: 20140018422
    Abstract: Disclosed herein are derivatives of tetracaine that, among other things, block cyclic nucleotide gated (CNG) channels and are useful in the treatment of diseases characterized by overactive CNG channels such as retinal degeneration diseases.
    Type: Application
    Filed: December 14, 2012
    Publication date: January 16, 2014
    Inventors: Jeffrey Karpen, Sarah Kirk, Adriana Andrade, Michelle Schaffer, Kenneth Melich
  • Publication number: 20130338375
    Abstract: A thioamide compound represented by the following general formula (1); wherein, in the general formula (1), R1 represents one of —OR11 and —NR12R13; R2 and R3 each independently represent one of a protecting group of an amide group and a hydrogen atom; the R11 represents one of a protecting group of a hydroxyl group and a hydrogen atom; and the R12 and R13 each independently represent one of a protecting group of an amino group and a hydrogen atom, where the R12 and R13 may together form a protecting group having a cyclic structure.
    Type: Application
    Filed: August 20, 2013
    Publication date: December 19, 2013
    Applicant: Microbial Chemistry Research Foundation
    Inventors: Masakatsu SHIBASAKI, Naoya KUMAGAI
  • Patent number: 8581004
    Abstract: Disclosed are compounds of Formula (I) and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: November 12, 2013
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Teresa Kowalczyk-Przewloka, Lijun Sun
  • Publication number: 20130289122
    Abstract: Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical compositions containing them are useful as sodium and/or calcium channel modulators for preventing, alleviating and curing pathologies wherein the above mechanisms play a pathological role. The compounds may be particularly useful for the prevention, alleviation, and curing of, for example, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases.
    Type: Application
    Filed: March 11, 2013
    Publication date: October 31, 2013
    Inventor: Newron Pharmaceuticals S.P.A.
  • Patent number: 8536227
    Abstract: The present invention provides new tyrphostin derivatives acting as protein kinase (PK) and receptor kinase (RK) signaling modulators. The invention further provides methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PK and RK related disorders such as metabolic, inflammatory, fibrotic, and cell proliferative disorders, in particular cancer.
    Type: Grant
    Filed: June 7, 2009
    Date of Patent: September 17, 2013
    Assignee: Novotyr Therapeutics Ltd.
    Inventors: Hadas Reuveni, Alexander Levitzki, Revital Sasson, Andre C. B. Lucassen
  • Publication number: 20130231478
    Abstract: The invention discloses a novel intermediate for preparing tapentadol and analogues thereof, wherein the structural formula is shown as formula I or II, and the groups are defined as the specification. The invention further discloses a method for preparing the novel intermediate and use of the intermediate for preparing tapentadol and analogues thereof. The invention can remarkably improve the product yield and quality of tapentadol, reduce the production cost, and simplify the production procedure. The preparation process is environment friendly, thus more suitable for the requirements of industrial production.
    Type: Application
    Filed: July 29, 2011
    Publication date: September 5, 2013
    Inventors: Ziao Xu, Yuanhai Zhao, Degang Li, Xiaoxiang Li
  • Patent number: 8461199
    Abstract: The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thiohydrazide amide] is represented by Structural Formula (I): or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. The present invention also provides a pharmaceutical composition comprising a compound of the invention and method of use thereof.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: June 11, 2013
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Nagai Masazumi, Jianhua Shen
  • Publication number: 20130102774
    Abstract: A process for transforming a group >C?O (I) in a compound into a group >C?S (II) or into a tautomeric form of group (II) in a reaction giving a thionated reaction product, by use of crystalline P2S5.2 C5H5N as a thionating agent. A thionating agent which is crystalline P2S5.2 C5H5N.
    Type: Application
    Filed: February 3, 2012
    Publication date: April 25, 2013
    Applicant: VIRONOVA AB
    Inventors: Birgitta Pettersson, Vedran Hasimbegovic, Per H Svensson, Jan Bergman
  • Patent number: 8420855
    Abstract: A compound of formula (I), wherein A1, A2, A3, A4, R1, R2, G1, G2, Q1 and Q2 are as defined in claim 1; or salts or N-oxides thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and control insect, acarine, mollusc and nematode pests.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: April 16, 2013
    Assignee: Syngenta Crop Protection LLC
    Inventors: Peter Maienfisch, Werner Zambach, Pierre Jung, William Lutz, Thomas Pitterna, Peter Renold
  • Patent number: 8394858
    Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: March 12, 2013
    Assignee: Novartis AG
    Inventors: David Barnes, Gregory Raymond Bebernitz, Scott Louis Cohen, Robert Edson Damon, Robert Francis Day, Monish Jain, Rajeshri Ganesh Karki, Louise Clare Kirman, Tajesh Jayprakash Patel, Brian Kenneth Raymer, Herbert Franz Schuster, Wei Zhang
  • Publication number: 20120270940
    Abstract: This invention relates to the field of biologically active compounds and specifically to closthioamides, pharmaceutical compositions comprising these compounds, and their use as antibiotic, antifungal, and/or cytotoxic agent.
    Type: Application
    Filed: November 2, 2010
    Publication date: October 25, 2012
    Applicant: LELBUIZ-INSTITUT FUR NATURSTOFF-FORSCHUNG UND INFE
    Inventors: Swantje Behnken, Hans-Martin Dahse, Christian Hertweck, Keishi Ishida, Thorger Lincke, Martin Roth, Florian Kloss
  • Publication number: 20120078013
    Abstract: Disclosed is a method appropriate for safely, economically and easily producing at a high yield a 4-substituted benzothioamide derivative which is useful as an intermediate in the production of a 2-(3-cyanophenyl)thiazole derivative useful as a drug for gout. Specifically disclosed is a method for producing a 4-substituted benzothioamide derivative represented by formula (A).
    Type: Application
    Filed: June 8, 2010
    Publication date: March 29, 2012
    Applicant: TEIJIN PHARMA LIMITED
    Inventor: Satoshi Sugiura
  • Publication number: 20120065206
    Abstract: The present invention is directed to compounds represented by structural formula (I), or a pharmaceutically acceptable salt or a transition metal chelate, coordinate or complex thereof or a transition metal chelate, coordinate or complex of a deprotonated form of the compound. Pharmaceutical composition and method of use for these compounds are also included.
    Type: Application
    Filed: December 1, 2009
    Publication date: March 15, 2012
    Applicant: SYNTA PHARMACEUTICALS CORP.
    Inventors: Jun Jiang, Teresa Kowalczyk-Przewloka, Stefan M. Schweizer, Zhi-Qiang Xia, Shoujun Chen, Christopher Borella, Lijun Sun
  • Publication number: 20120004310
    Abstract: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.
    Type: Application
    Filed: May 27, 2011
    Publication date: January 5, 2012
    Inventors: Frank M. LONGO, Stephen M. Massa, Sandeep Gupta
  • Publication number: 20110319616
    Abstract: An object is to provide a thiazole derivative produced from easily available raw materials by a simplified production process. Provided are a process for producing a novel thiazole derivative represented by the general formula (I), which is characterized by adding a strong base to a thioamide represented by the general formula (II) and reacting the mixture with a thioformamide represented by the general formula (III), and a novel thiazole derivative.
    Type: Application
    Filed: March 8, 2010
    Publication date: December 29, 2011
    Applicant: GIFU UNIVERSITY
    Inventor: Toshiaki Murai
  • Publication number: 20110288162
    Abstract: The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thio-hydrazide amide] is represented by Structural Formula (I): or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. The present invention also provides a pharmaceutical composition comprising a compound of the invention and method of use thereof.
    Type: Application
    Filed: October 21, 2009
    Publication date: November 24, 2011
    Applicant: SYNTA PHARMACEUTICAL CORP
    Inventors: Nagai Masazumi, Jianhua Shen
  • Patent number: 8043702
    Abstract: A surface-modified, magnetic nanoparticle has one or more multi-dentate ligands bound to a surface of a magnetic nanoparticle. The one or more multi-dentate ligands are bound to the surface of the magnetic nanoparticle through one or more dithiocarbamate groups. The one or more multi-dentate ligands may be a compound of Formula II: R2NCH2[CH2NR?CH2]m[CH2N(CS2?)CH2]q[CH2NHCH2]rCH2NR?2 ??(II) where each R, R?, and R? are independently H, a branched ethyleneimine unit, an unsubstituted or substituted alkyl, an unsubstituted or substituted alkenyl, or an unsubstituted or substituted aryl; and n is an integer from 1 to about 50.
    Type: Grant
    Filed: August 25, 2008
    Date of Patent: October 25, 2011
    Assignee: Seoul National University Research & Development Business Foundation (SNU R&DB Foundation)
    Inventor: Jin-Kyu Lee
  • Publication number: 20110245262
    Abstract: Disclosed are compounds and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also, disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: August 20, 2007
    Publication date: October 6, 2011
    Inventors: Lijun Sun, Keizo Koya, Shoujun Chen, Zachary Demko, Zhi-Qiang Xia
  • Publication number: 20110196025
    Abstract: At least 70% by weight of Compound 1 is the single crystalline form, Form A, Form C, or Form D, of the compound. A pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent, and compound 1, wherein at least 70% by weight of the compound is the single crystalline form, Form A, Form C, or Form D, of the compound. A method of treating a subject with cancer comprises administering to the subject an effective amount of compound 1 or the pharmaceutical composition.
    Type: Application
    Filed: November 28, 2008
    Publication date: August 11, 2011
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Elena I. Kostik, Lijun Sun, Joanna Dziewiszek, Jun Y. Choi
  • Patent number: 7981954
    Abstract: Methods for controlling atmospheric corrosion of a metallic surface including coating the metallic surface with a coating material containing at least one compound having at least one thioamide group.
    Type: Grant
    Filed: January 26, 2006
    Date of Patent: July 19, 2011
    Assignee: BASF Aktiengesellschaft
    Inventors: Gerhard Fischer, Monica Fernandez Gonzalez, Marc Schroeder, Konrad Roschmann, Alexander Goethlich, Hermann Bergmann, Guido Vandermeulen
  • Publication number: 20110105618
    Abstract: The present invention provides new tyrphostin derivatives acting as protein kinase (PK) and receptor kinase (RK) signaling modulators. The invention further provides methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PK and RK related disorders such as metabolic, inflammatory, fibrotic, and cell proliferative disorders, in particular cancer.
    Type: Application
    Filed: June 7, 2009
    Publication date: May 5, 2011
    Applicant: NOVOTYR THERAPEUTICS LTD.
    Inventors: Hadas Reuveni, Alexander Levitzki, Revital Sasson, Andre C. B. Lucassen
  • Publication number: 20110098476
    Abstract: Disclosed herein are methods of preparing a bis(thio-hydrazide amides) compounds of the following structural formula: wherein R1, R2, R3, R4, R5, R6 and R13 are defined herein.
    Type: Application
    Filed: March 31, 2009
    Publication date: April 28, 2011
    Inventors: Shoujun Chen, Jun Jiang, Lijun Sun, Keizo Koya
  • Patent number: 7923576
    Abstract: The invention relates to tuned multifunctional linker molecules for charge transport through organic-inorganic composite structures. The problem underlying the present invention is to provide multifunctional linker molecules for tuning the conductivity in nanoparticle-linker assemblies which can be used in the formation of electronic networks and circuits and thin films of nanoparticles. The problem is solved according to the invention by providing a multifunctional linker molecule of the general structure CON1-FUNC1-X-FUNC2-CON2 in which X is the central body of the molecule, FUNC1 and FUNC2 independently of each other are molecular groups introducing a dipole moment and/or capable of forming intermolecular and/or intramolecular hydrogen bonding networks, and CON1 and CON2 independently of each other are molecular groups binding to nanostructured units comprising metal and semiconductor materials.
    Type: Grant
    Filed: January 3, 2006
    Date of Patent: April 12, 2011
    Assignee: Sony Deutschland GmbH
    Inventors: Jurina Wessels, William Ford, Akio Yasuda
  • Patent number: 7872152
    Abstract: The present invention is generally drawn to novel isolated therapeutic agents, termed resolving, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (PUFA) such as eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), cyclooxygenase-II (COX-2) and an analgesic, such as aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy EPA or DHA compounds having unique structural and physiological properties. The present invention therefore provides for many new useful therapeutic di- or tri-hydroxy derivatives of EPA or DHA (resolvins) that diminish, prevent, or eliminate inflammation or PMN migration, for example. The present invention also provides methods of use, methods of preparation, and packaged pharmaceuticals for use as medicaments for the compounds disclosed throughout the specification.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: January 18, 2011
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Charles N. Serhan, Bruce D. Levy
  • Publication number: 20100249239
    Abstract: Disclosed herein are compositions comprising a compound represented by structural formula (I): 2 g of which is reconstitutable in 10 mL of a water in less than 10 minutes, and methods for preparing these compositions. Also disclosed are compositions comprising a compound represented by structural formula (I) and a pharmaceutically acceptable excipient, wherein the molar ratio of said compound to said excipient is from 1:20 to 1:1, and methods for preparing these compositions.
    Type: Application
    Filed: February 1, 2010
    Publication date: September 30, 2010
    Inventors: Walter J. Lunsmann, Ninad Deshpanday
  • Publication number: 20100221809
    Abstract: This invention is directed to compositions and methods for the isolation and further characterization of eukaryotic, mammalian, and/or human PC-PLC. In addition, the present invention discloses methods for the synthesis of an affinity chromatography resin for the isolation and purification of biologically active proteins, including eukaryotic PC-PLC.
    Type: Application
    Filed: December 15, 2009
    Publication date: September 2, 2010
    Inventors: Henry J. Forman, Matthew P. Meyer
  • Patent number: 7750042
    Abstract: One embodiment of the present invention is a compound represented by the Structural Formula (I): Y is a covalent bond of a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C?Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 is an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, or a substituted non-aromatic heterocyclic group, R2-R4 are independently —H, an aliphatic group, a substituted aliphatic group, a non-aromatic heterocyclic group, a substituted non-aromatic heterocyclic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: July 6, 2010
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Keizo Koya, Lijun Sun, Shoujun Chen, Noriaki Tatsuta, Yaming Wu, Mitsunori Ono, Zhi-Qiang Xia
  • Publication number: 20100130565
    Abstract: The present invention relates to novel thioamide derivatives of formula (I) and formula (Ia): wherein, R3, R4, R5, R6, R7, P, Q, T, V, W, X, Y, Z, a, m and n are as defined in the description, compositions thereof, processes for their preparation and their uses as pesticides.
    Type: Application
    Filed: October 20, 2009
    Publication date: May 27, 2010
    Inventors: Loic Patrick Le Hir de Fallois, Hyoung Ik Lee, Philip Reid Timmons
  • Patent number: 7714168
    Abstract: Since an amide compound represented by the formula (1) is effective for controlling plant diseases, it is useful as an effective ingredient of a composition for controlling plant diseases.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: May 11, 2010
    Assignee: Sumitomo Chemical Company, Limited
    Inventor: Takashi Komori
  • Patent number: 7709683
    Abstract: A method of preparing a bis(thio-hydrazide amide) disalt includes the steps of combining a neutral bis(thio-hydrazide amide), an organic solvent and a base to form a bis(thio-hydrazide amide) solution; and combining the solution and methyl tert-butyl ether, thereby precipitating a disalt of the bis(thio-hydrazide amide). In some embodiments, a method of preparing a bis(thio-hydrazide amide) disalt includes the steps of combining a neutral bis(thio-hydrazide amide) and an organic solvent selected from methanol, ethanol, acetone, and methyl ethyl ketone to make a mixture; adding at least two equivalents of a base selected from sodium hydroxide, potassium hydroxide, sodium methoxide, potassium methoxide, sodium ethoxide and potassium ethoxide to the mixture, thereby forming a solution; and combining the solution and methyl tert-butyl ether to precipitate the disalt of the bis(thio-hydrazide amide).
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: May 4, 2010
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Zhi-Qiang Xia
  • Publication number: 20100093828
    Abstract: Disclosed are compounds of formula (IA), formula (IV) or formula (V), and pharmaceutical compositions containing them which are useful for treating a subject with a proliferative disorder, such as cancer. The disclosed compounds and pharmaceutical compositions are also useful for treating disorders responsive to Hsp70 induction and/or natural killer induction.
    Type: Application
    Filed: August 20, 2007
    Publication date: April 15, 2010
    Inventors: Keizo Koya, Lijun Sun, Shoujun Chen, Jun Jiang
  • Publication number: 20100081635
    Abstract: Disclosed are compounds of formulae (I), (III), (IV), (VII), (X), (XI), (XII), (XIII) and (XIV), wherein the variabables are as defined in the claims, and methods of using compounds of the invention for treating a subject with a proliferative disorder, such as cancer, and methods for treating disorders responsive to Hsp70 induction and/or natural killer induction. Also disclosed are pharmaceutical compositions comprising compounds of the invention and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: August 20, 2007
    Publication date: April 1, 2010
    Inventors: Shoujun Chen, Keizo Koya, Zachary Demko, Lijun Sun
  • Publication number: 20100056635
    Abstract: The present invention provides new tyrphostin derivatives acting as substrate competitive protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PTK and RTK related disorders such as metabolic, fibrotic, and cell proliferative disorders, in particular psoriasis and cancer.
    Type: Application
    Filed: December 4, 2007
    Publication date: March 4, 2010
    Inventors: Hadas Reuveni, Alexander Levitzki, Lilach Steiner, Revital Sasson, Iris Ben-David, Avi Weissberg
  • Patent number: 7671092
    Abstract: Disclosed is a compound represented by the Structural Formula (I): Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R5-R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R7 and R8 are each independently —H, an aliphatic or substituted aliphatic group, or R7 is —H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is ?O or ?S.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: March 2, 2010
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Keizo Koya, Lijun Sun, Shoujun Chen, Noriaki Tatsuta, Yaming Wu, Mitsunori Ono
  • Patent number: 7652168
    Abstract: Disclosed is a method of preparing a thiohydrazide product compound from a hydrazide starting compound. The hydrazide starting compound is represented by Structural Formula (I): The thiohydrazide product compound is represented by Structural Formula (II): In Structural Formulas (I)-(II), R1 and R2 are independently an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R2 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. When R2 is an aryl group or a substituted aryl group, then R5 is a hydrazine protecting group; and when R2 is an aliphatic or substituted aliphatic group, then R5 is —H or a hydrazine protecting group. R10 is —H or a substituted or unsubstituted alkyl group. The method comprising the step of reacting the starting compound with a thionylating reagent.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: January 26, 2010
    Assignee: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Lijun Sun, Zhi-Qiang Xia, Keizo Kova, Mitsunori Ono